In human natural killer (NK) cells, human cytomegalovirus (HCMV) has been shown to be a driving force capable of inducing the expansion of a highly differentiated NKG2C + CD57 + subset, persisting over time in both HCMV + healthy subjects and umbilical cord blood transplantation (UCBT) recipients experiencing HCMV viral reactivation. In HCMV + healthy subjects, such expanded NK-cells are characterized by epigenetic modifications that modulate their phenotypic and functional characteristics. In particular, an enhanced ADCC activity is detectable in NK cells lacking the signaling protein FcεRγ. Timing and mechanisms involved in the acquisition of HCMV-induced, adaptive-like features by NK cells are currently unknown. In this study, we investigated the de novo acquisition of several adaptive features in NK cells developing after UCBT by monitoring NK-cell differentiation for at least 2 years after transplant. In UCBT recipients experiencing HCMV reactivation, a rapid phenotypic reconfiguration occurred resulting in the expected expansion of CD56 dim NKG2C + CD57 + NK cells. However, while certain HCMV-driven adaptive hallmarks, including high KIR, LILRB1, CD2 and low/negative NKG2A, Siglec-7, and CD161 expression, were acquired early after UCBT (namely by month 6), downregulation of the signaling protein FcεRγ was detected at a later time interval (i.e., by month 12). This feature characterized only a minor fraction of the HCMV-imprinted NKG2C
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dim NK cell subset, while it was detectable in higher proportions of CD57 + NK cells lacking NKG2C. Interestingly, in patients developing a hyporesponsive CD56 − CD16 bright NK-cell subset, FcεRγ downregulation occurred in these cells earlier than in CD56 dim NK cells. Our data suggest that the acquisition of a fully "adaptive" profile requires signals that may lack in UCBT recipients and/or longer time is needed to obtain a stable epigenetic reprogramming. On the other hand, we found that both HCMV-induced FcεRγ neg and FcεRγ + NK cells from these patients, display similar CD107a degranulation and IFN-γ production capabilities in response to different stimuli, thus indicating that the acquisition of specialized effector functions can be achieved before the "adaptation" inTrODUcTiOn Natural killer (NK) cells are a lymphoid population belonging to the innate immunity capable of providing rapid responses against tumors and viral infections without prior sensitization (1) . Their activity is regulated by germ-line encoded inhibitory and activating receptors (2) (3) (4) and can be modulated by cytokines/ chemokines, PAMPS, and education mechanisms (5) .
It is known since several years that viral infections, primarily those due to human cytomegalovirus (HCMV), shape the NK cell receptor repertoire and influence NK cell development and function (6, 7) . In particular, initial studies revealed that HCMV infection may induce a stable expansion of a NK cell subset expressing the activating receptor CD94/NKG2C and displaying a differentiated phenotype mainly NKG2A
in healthy individuals (8) . It was suggested that the NKG2C receptor could play a crucial role in favoring this expansion by interacting with ligands on HCMV-infected target cells (9) . In particular, the expression of non-classic HLA-class I molecule HLA-E, which represents the only known ligand for NKG2C (10) , is necessary to induce proliferation of NKG2C + NK cell (11) . Subsequently, based on results emerging in murine models of CMV infection (12) , the imprinting exerted by HCMV on NK cells has been further investigated and reinterpreted, revealing unexpected adaptive features displayed by HCMV-induced NK cells, namely (oligo)clonal expansion, enhanced effector function, longevity, as well as epigenetic modifications (13, 14) . Thus, the so called memory-like NKG2C +
CD57
+ NK cell subset was shown to display an epigenetic remodeling at the IFN-γ locus, similar to that found in effector memory T cells, which is likely to be responsible for the enhanced IFN-γ production upon target cell recognition detectable in NKG2C + NK cells (15) . Moreover, in HCMV + healthy individuals, a variable proportion of NK cells, mainly (but not exclusively) belonging to the NKG2C + subset, were characterized by a decreased expression of signaling molecules, such as the adaptor proteins FcεRγ and EAT-2, and the tyrosine kinase Syk. In addition, these cells displayed a lower expression of the transcription factor PLZF, which is involved in the regulation of epigenetic modifications (e.g., DNA hypo-/hypermethylation) that, in turn, influence the expression of receptors and adaptor proteins (16, 17) . These NK cells, showing hallmarks of adaptive immunity, are now often referred to as adaptive NK cells (18) (19) (20) . Among the above adaptive features, the lack of FcεRγ was more frequently detected (16, 17) . It has been proposed that this event may favor more efficient ADCC responses against Ab-coated HCMV-infected targets by such adaptive FcεRγ neg NK cells (17, 21, 22) . However, the precise mechanisms regulating the generation of adaptive NK cells, as well as the time when different adaptive traits are acquired after HCMV infection, are not fully elucidated.
The imprinting induced by HCMV infection may vary among individuals, but it is particularly strong in immunocompromised subjects, such as patients undergoing hematopoietic stem cell transplantation (HSCT). Indeed, following HCMV infection/ reactivation, a rapid reconstitution of a differentiated KIR + NKG 2A − NKG2C
+ CD57 + NK cell subset, which expands and persists over time, was initially detected in patients receiving umbilical cord blood transplantation (UCBT) (23, 24) . Thus, NK cells generated after HSCT appeared to undergo a viral-induced (oligo) clonal expansion and to be long living. These findings that contributed to the concept of adaptive NK cells, prompted us to investigate the emergence of the HCMV-induced adaptive features in NK cells reconstituting after UCBT. This transplantation setting, in which the graft is composed of HSC precursors and naive lymphoid cells, allows the identification of de novo generated adaptive NK cells. By focusing on some of the most relevant adaptive characteristics (FcεRγ, PLZF, and selected surface receptors expression), we could monitor their acquisition by NK cells undergoing differentiation in patients experiencing HCMV reactivation in an ample time window after UCBT (1-24 m).
We show that, despite a remarkable expansion of mature NKG2C + CD57 + NK cells showing several HCMV-driven hallmarks (high KIR, LILRB1, CD2, low/negative NKG2A, Siglec-7, CD161), the downregulation of the signaling protein FcεRγ (a crucial adaptive trait) appeared late after transplantation. In addition, FcεRγ downregulation occurred only in a minor fraction of the HCMV-imprinted NKG2C
+

CD57
+ CD56 dim NK cell subset, while it was detectable in slightly higher proportions of mature NKG2C
−
CD57
+ NK cells. This finding suggests that the acquisition of a fully adaptive signature requires either signals that may lack in UCBT recipients or longer times to obtain a stable epigenetic reprogramming.
MaTerials anD MeThODs
Patients, samples, and ethical statements
Seventeen patients with hematological malignancies (7 children and 10 adults), mostly acute myeloid leukemia, were included in this study. All patients received UCBT at the Bambino Gesù Children's Hospital, Rome, Italy (pediatric patients) or at the San Martino Hospital, Genoa, Italy (adult patients). Either patients or their parents gave their informed consent to participation in this study, which was approved by the Azienda Ospedaliera Universitaria San Martino (Genoa, Italy), by the University of Genoa and by the Bambino Gesù Children's Hospital (Rome, Italy) ethics committees and was conducted in accordance with the tenets of the Declaration of Helsinki. Details on patients' clinical characteristics are summarized in Table S1 in Supplementary Material. All patients received a combination of cyclosporine-A to HCMV is completed. Our study provides new insights in the process leading to the generation of different adaptive NK-cell subsets and may contribute to develop new approaches for their employment as novel immunotherapeutic tools.
Keywords: adaptive natural killer cells, Fcεrγ, human cytomegalovirus reactivation, nKg2c-cD57, UcB transplant, aDcc (Novartis Pharma), mycophenolate mofetil (Roche), and an antithymocyte globulin (Genzyme) as graft-versus-host disease (GvHD) prophylaxis. Cyclosporine-A was started intravenously from day −7 before transplantation at a daily dose of 1 mg/kg recipient body weight. The dose of cyclosporine-A was adjusted to maintain a serum trough level between 150 and 300 µg/L. After engraftment, cyclosporine-A was given orally and, starting from day +90 after UCBT, progressively tapered until discontinuation. Mycophenolate mofetil was administered at a dosage of 15 mg/kg twice a day from day 1 to day 28 after transplantation. Antithymocyte globulin was given before transplantation at a dose of 2-3 mg/kg on days −3 and −2. No patients received steroids for GvHD prophylaxis.
Peripheral blood samples were collected from patients at 1, 6, 12, and 24 months after transplantation. Peripheral blood mononuclear cells (PBMC) were separated from blood samples by Ficoll-Hypaque gradients (Sigma-Aldrich, St. Louis, MO, USA), frozen, and subsequently thawed for flow cytometry analyses and functional assays. Three HCMV-reactivating patients received UCBT from donors carrying NKG2C gene homozygous deletion (see Results); therefore, NK cells isolated from these patients were analyzed separately and are not included in those assays based on NKG2C expression evaluation.
Peripheral blood mononuclear cells collected from adult healthy donors (HD) and UCB units provided by Centro Trasfusionale Azienda Ospedaliera Universitaria San Martino (Genoa, Italy), were used as controls.
hcMV serology and Therapy
Human cytomegalovirus serology was assessed prior to transplantation using enzyme-linked immunoassay for virus-specific immunoglobulin IgM and IgG. Patients were monitored for HCMV reactivation in blood by determination of DNAemia twice a week from day 0 until discharge from the hospital, and then once a week for the first 3 months. Subsequently, patients were monitored for HCMV at time of control medical visits or in the presence of clinical symptoms suggestive of HCMV infection. HCMV reactivation was monitored in the posttransplant period by antigenemia determination, counting HCMV pp65 + cells/2 × 10 5 PMN cells. Pre-emptive therapy was based on administration of i.v. ganciclovir (5 mg/kg twice a day), replaced by foscarnet (90 mg/kg twice a day) in case of ganciclovir-induced neutropenia (less than 0.5 × 10 9 neutrophils/L) or sustained increase of HCMV levels in blood during therapy with ganciclovir. Antiviral treatment was discontinued after virus clearance from blood, defined as two consecutive negative results. Episodes of HCMV relapse were treated similarly. Details on HCMV reactivation episodes and serology are reported in Table S1 in Supplementary Material.
Monoclonal antibodies (mabs) and Flow cytometry
The following mAbs, produced in our laboratory, were used in this study: C127 (IgG1, anti-CD16), MA311 (IgG1, anti-CD161), MAR206 (IgG1, anti-CD2), PP35 (IgG1, anti-CD244), Z199 (IgG2b, anti-NKG2A), QA79 (IgG1, anti-Siglec-7), DF200 (IgG1, anti-KIR2DL1/S1/L2/S2/L3/S5), AZ158 (IgG2a, anti-KIR3DL1/ S1/L2), 11PB6 (IgG1, anti-KIR2DL1 and KIR2DS1), GL183 (IgG1, anti-KIR2DL2/L3/S2), FES172 (IgG2a, anti-KIR2DS4), and Z27 (IgG1, anti-KIR3DL1/S1). F278 (IgG1, anti-LILRB1/ ILT-2) was kindly provided by Dr. D. Pende. The following commercial antibodies were used: anti-NKG2C (134522 clone), anti-KIR2DL1/KIR2DS5-FITC or -APC (143211 clone) were purchased from R&D Systems (Abingdon, UK); anti-CD56-PC7 (N901 clone) and anti-NKG2A-APC (z199 clone) were purchased from Beckman Coulter, Immunotech (Marseille, France); anti-CD3-VioGreen (BW264/56 clone), anti-CD19-VioGreen (LT19 clone), anti-CD14-Viogreen (TUK4 clone), anti-CD33-Viogreen (REA775 clone), anti-CD57-Vioblue (TB03 clone), biotin-conjugated anti-NKG2A (REA110 clone), anti-KIR2DL2/L3-S2-APC (DX27 clone), anti-KIR2DL1/S1-FITC (11PB6 clone), anti-KIR3DL1-FITC (DX9 clone), and antibiotinPerCPVio700 mAbs were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany); anti-CD16-PerCP-Cy5.5 (clone 3G8), anti-KIR2DL2/L3-S2-FITC (CH-L clone), anti-CD161-PE (C3H clone), anti-CD107a-APC-H7 (anti-LAMP1), anti-IFN-γ-PE, and anti-Syk-PE were from BD Biosciences (San Diego, CA, USA); MilliMark anti-FcεRγsubunit-FITC was purchased from Sigma-Aldrich; anti-Syk-FITC, anti-CD3ζ-PE, anti-PLZF-PE, and anti-T-bet-PE were purchased from eBioscience Inc. (San Diego, CA, USA); anti-human HLA-E (3D12 clone, IgG1) was purchased from Abnova (Taipei, Taiwan). Goat anti-mouse isotype-specific secondary reagents were purchased from Southern Biotech (Birmingham, AL, USA) and Jackson ImmunoResearch Laboratories (Suffolk, UK). Appropriated isotype controls were used when fluorochrome-labeled mAbs were employed.
Natural killer cell phenotype and effector functions were mainly analyzed on thawed PBMC, gating NK cells by physical parameters and by the combined use of anti-CD56, anti-CD16, anti-CD3, anti-CD19, anti-CD14 mAbs. To evaluate the presence of the CD56
−
CD16
bright NK cell subset, anti-CD33 mAb has been included in the gating strategy. The whole CD56 dim NK cell subset or the different NKG2C/CD57 CD56 dim subsets were evaluated whenever indicated (see gating strategy in Figure  S1 in Supplementary Material). For intracellular cytofluorimetric analyses, cells were fixed and permeabilized with Foxp3 permeabilization buffer Kit (Miltenyi Biotec) according to the manufacturer's instructions.
Cytofluorimetric analyses were performed on eight-colors BD FACSVerse (Becton Dickinson, Mountain View, CA, USA), and data were analyzed by FACSuite software version 1.0.5.
Functional assays
The medium used throughout the experiments was RPMI 1640, supplemented with 2 mM l-glutamine, 1% penicillin-streptomycin-neomycin mixture, and 10% heat-inactivated FCS. PBMC were cultured overnight in the presence of rhIL-15 (Peprotech, London, UK) at a final concentration of 10 ng/mL, washed, and used in the different assays. In reverse Ab-dependent cellular functional assays, PBMC from UCBT patients and HCMV + HD were incubated with the FcγR + p815 murine mastocytoma cell line, either in the presence or in the absence of mAbs (5 or 0.1 µg/mL for anti-CD16 and 0.05 µg/mL for anti-NKG2C) specific for different surface receptors indicated in the text and figures at an E:T ratio of 1:1 (where effector cells represent the effective number of PB-NK cells) for 4 h in culture medium supplemented with anti-CD107a-APC-H7 mAb and Golgi Stop (BD Biosciences Pharmingen) that was added for the last 3 h of culture. Cells were stained with anti-NKG2C and anti-NKG2A-biotin mAbs for 35 min on ice. Thereafter, cells were washed and stained with appropriate secondary reagents and anti-CD56-PC7, anti-CD57 vioblue and anti-CD3 and anti-CD19-viogreen for 35 min on ice. After staining, cells were fixed and permeabilized with Foxp3 permeabilization buffer Kit. IFN-γ production was detected on FcεRγ + and FcεRγ neg NK-cell subsets by subsequent intracellular staining with anti-IFN-γ-PE and anti-FcεRγ-FITC and cytofluorimetric analysis. The percentage of positive cells was calculated by subtracting the baseline CD107a or IFN-γ expression in control cultures (i.e., without stimuli from targets).
In different assays, degranulation and IFN-γ production were analyzed on FcεRγ + and FcεRγ neg NK cell subets from PBMC stimulated with Raji cell line, previously coated or not with the human anti-CD20 Rituximab (1 µg/mL), at an E:T ratio of 1:1, for 4 h in culture medium supplemented with anti-CD107a-APC-H7 mAb and Golgi Stop in the last 3 h of culture. Cells were then stained, permeabilized, and analyzed as described above.
cFse Proliferation assays
Peripheral blood mononuclear cells were labeled with the intracellular fluorescent dye 5(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes, Life Technologies, OR, USA). Briefly, extensively washed PBMC were resuspended in RPMI (10 7 /mL) and incubated for 10 min at 37°C with CFSE (2.5 µM). After three washes, CFSE-labeled PBMC were cultured either in the presence or in the absence of irradiated lymphoblastoyd 721.221wt cell line (221wt) or 721.221AEH cell line [221AEH, kind gift from prof. Miguel Lopez-Botet and dr. Aura Muntasell, originally developed by Geraghty D. et al. (25) ] that has been transfected with a hybrid HLA-E containing the HLA-A2 signal sequence, at an E:T ratio (NK:221) of 5:1. Cocultures were kept in culture medium containing rhIL-2 (Proleukin, Chiron Corp., Emeryville, CA, USA) at a final concentration of 50 UI/mL. FACS analyses were performed at 7, 10, and 14 days as described above. NK cells cultured in the presence of 221AEH were analyzed for FcεRγ expression at 14th day of culture (i.e., when NK cells, upon proliferation, had undergone the complete dilution of the CFSE dye). After surface staining, cells were fixed and permeabilized as described above and subsequently stained with anti-FcεRγ-FITC mAb.
genotyping of nKg2c-Deleted haplotype DNA of the tested samples was extracted using QIAamp DNA Blood Mini kit (Qiagen, Hilden, Germany). The presence or absence of the NKG2C gene was determined as previously described with minor modifications (26) . In particular, in each PCR reaction three sets of primers are present: the two primer pairs that allow discriminating between the haplotypes in which the NKG2C gene was present and those in which it was absent, in combination with the set specific for the NKG2A gene. The PCR conditions consisted of an initial denaturation at 95°C for 2 min, followed by 35 cycles: 30 s at 95°C, 30 s at 55°C, and 30 s at 72°C.
statistical analysis
Wilcoxon-Mann-Whitney nonparametric tests were employed. The statistical significance (p value) is indicated (*p < 0.05; **p < 0.01; ***p < 0.001). Median fluorescence intensity (MFI) values were normalized before calculating statistical significance. Graphic representations and statistical analyses were performed with GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA).
resUlTs
Fcεrγ neg cD56 dim nK cells Develop late and in small Proportions in hcMVreactivating UcBT recipients
In order to acquire insights in the generation of HCMV-induced, adaptive NK cells, we analyzed the FcεRγ expression in developing NK cells collected at different time points from a cohort of patients undergoing UCBT. In previous studies (23, 27) , we showed that, in UCBT recipients experiencing HCMV reactivation (usually occurring within month 1-2 after transplantation), NK cell maturation was highly accelerated. In addition, a population of CD56 dim NK cells expressing NKG2C was greatly expanded and progressively acquired CD57, a marker typical of terminally differentiated NK cells. In the present study, we monitored the FcεRγ expression on CD56 dim NK cells. Despite Figure 1B ), while they were virtually undetectable both in UCBT recipients who did not experience HCMV reactivation (shown at 1 or 12 m) and in reactivating UCBT recipients early after HSCT (1-6 months). Notably, in HCMV-reactivating patients, the percentages of FcεRγ neg CD56 dim NK cells were only slightly increased at 24 months after UCBT.
As expected, NK cells isolated from healthy controls including cord blood (CB) and HCMVseronegative healthy donors (HD − ), did not display FcεRγ downregulation ( Figure 1B) . Notably, NK cells from HCMV seropositive healthy donors (HD + ) were characterized by variable amounts of FcεRγ neg cells (ranging from 2 to 95% with a median value of 20%, Figure 1B ). On the other hand, in all cases, the adaptor protein CD3ζ was expressed by virtually all CD56 dim NK cells (data not shown). The CD56 bright NK cell subset consistently expressed both FcεRγ and CD3ζ, although at slightly lower levels than CD56 dim NK cells (data not shown). In Figure 1C , FcεRγ expression in CD56 dim NK cells is shown for two representative patients (one who did and the other who did not experience HCMV reactivation), in comparison to healthy controls either HCMV − (CB and PB from HD − ) or HCMV + (PB from HD + ). Analysis of Syk expression revealed an expression pattern similar to that of FcεRγ, with the exception of two patients in whom Syk resulted partially downregulated already at early times after UCBT (data not shown). 
CD57
+ subsets as compared to the other CD57 − subsets ( Figure 2B , white circles). However, despite a strong HCMVdriven imprinting that favored a large expansion of the memorylike NKG2C +
+ cells ( Figures 1A and 2B,C) , FcεRγ neg cells were preferentially present in the NKG2C −
+ subset. In fact, as shown in Figure 2D, 
− NK cells at 24 months (Figures 2B,C) . In Figure 2F , FcεRγ expression in the different NKG2C/CD57 subsets is shown for a representative HCMVreactivating patient in parallel to a representative HCMV + HD. Figure  S2 in Supplementary Material). This suggests that, at variance with HD, in UCBT recipients, the generation of FcεRγ neg cells in the NKG2C − CD57 + subset could be favored also by mechanisms independent from NKG2C copy number. Interestingly, in three HCMV-reactivating recipients receiving UCBT from NKG2C −/− UCB donors (i.e., carrying homozygous NKG2C gene deletion), we detected a marginal FcεRγ downregulation at 12 months after the allograft that only slightly increased at 24 months ( Figure 3A) . In these patients, characterized by an expansion of mature (NKG2C − ) NKG2A − KIR + CD57 +/− cells expressing aKIRs (27) According to recent reports, HCMV-induced adaptive NK cells, besides the lack of FcεRγ expression, may also display a peculiar expression profile of given surface receptors which is likely to be determined by a specific DNA hypo-or hypermethylation pattern (16, 17) . We analyzed some of these informative markers in CD56 dim NK cell subsets developing in HCMV-reactivating UCBT recipients. In parallel, we examined KIR and NKG2A expression to confirm the HCMV-driven skewing toward a mature KIR + NKG2A − profile. As expected (23) Figure 4A upper left panel) . Of note, CD161 was homogeneously expressed by all NK cells isolated from nonreactivating recipients, CB and HCMV − HD (data not shown). Similarly, the upregulation of CD2 expression was higher in NKG2C + NK cells (both CD57 + and CD57 − ) than in NKG2C
− cells already at 6 months in terms of MFI ( Figure 4A bottom left panel), while no significant differences were found in terms of percentages of positive cells ( Figure S3A in Supplementary Material). At variance with CD2 and CD161, the expression of LILRB1 was modified (upregulated) in both NKG2C + CD57 + and NKG2C − CD57 + NK cell populations and remained high over time ( Figure 4A upper right panel) . Finally, CD16 expression levels were significantly higher in NKG2C − CD57 + than in NKG2C + CD57 + cells by month 6 after UCBT (Figure 4A bottom right panel). As control, CD244 MFI was evaluated and did not show any significant difference among subsets (data not shown). These results are in line with data obtained in NK cells from HD experiencing HCMV infection (see Figure S3B in Supplementary Material).
Next, we investigated at early and late time points the expression of PLZF, a transcription factor involved in the regulation of epigenetic modifications that is either absent or reduced in adaptive NK cells (16) . As shown in Figure 4B , we could detect a slight decrease in PLZF expression levels in NKG2C +
+ as compared to more immature NKG2C − CD57
− NK subset. While this was only a tendency at 6 months after UCBT, it subsequently increased becoming statistically significant at 24 months. Although, in the NKG2C −
+ subset, PLZF expression levels had a tendency to decrease, data were not statistically significant. NKG2C +
− NK cells showed PLZF decrease both at 6 months and 24 months but without reaching statistical significance when compared to the other subsets. T-bet expression did not show significant differences among the various subsets. This was in line with what observed in HCMV + HD, in whom PLZF downregulation mainly affected NKG2C + CD57 + NK cells (Figure 4B right  panels) . It thus appears that after UCBT, HCMV can induce a potent reshaping of NK cell receptor repertoire long before FcεRγ downregulation. Such reconfiguration is characterized by a potent imprinting on NKG2C + CD57 + NK cells. Moreover, based on our observation, it is conceivable that PLZF dowregulation influenced the phenotypic reconfiguration prior to the FcεRγ downregulation ( Figure 4B ).
In line with the above observations indicating a rapid HCMV-induced phenotypic reconfiguration, followed by FcεRγ downregulation at late time points, we could not find any statistically significant difference between FcεRγ + and FcεRγ neg cell subsets at 24 Figure 5A) . Unexpectedly, this subset displayed FcεRγ downregulation earlier (namely at 6 months) and to a larger extent as compared to CD56 dim NK cells from the same patients ( Figure 5B) . The lack of FcεRγ did not occur in CD56 − CD16 bright NK cells isolated from CB, in which these cells can be easily detected (differently from adult PB where this subset is rare) (23, 34) (Figures 5A,B) . Moreover, as shown in Figures 5C,D Peripheral blood mononuclear cell (PBMC) from HCMV-reactivating patients (n = 6), collected at 24 months after UCBT, were cultured overnight in the presence of rhIL-15. PBMC were then washed and cultured in the presence or in the absence of the Raji cell line, previously coated or not with the human anti-CD20 Rituximab (1 µg/mL), at an E:T ratio of 1:1, for 4 h. Thereafter, IFN-γ production (left panel) and CD107a degranulation (right panel) were evaluated for the indicated NK cells subsets described in the figure. PBMC alone were virtually IFN-γ and CD107a negative in all subsets and were not depicted. 95%CI for the mean of CD107a/IFN-γ positive NK cells is shown for each subset. Statistical significance is indicated (*p < 0.05; **p < 0.01; ***p < 0.001). (c) After overnight culture, the same cells were incubated with the FcγR + murine p815 cell line either in the presence or in the absence of anti-CD16, anti-NKG2C (indicated as 2C), anti-CD2 monoclonal antibodies (mAbs) alone or in combination. CTR indicates cells cultured in the presence of p815 and in the absence of mAbs. (Figures 2B,C) .
Interestingly, CD56
− FcεRγ neg NK cells were found also in the NKG2C −
CD57
− subset at any time point analyzed. The CD56 −
CD16
bright FcεRγ neg NK cell subset was lineage negative (CD3, CD19, CD14, and CD33 negative) and expressed, in addition to CD3ζ (data not shown) and 2B4, high proportions of KIR and LILRB1 and low levels of NCRs and NKG2A ( Figure S5A in Supplementary Material) Previous studies suggested that the lack of FcεRγ could favor a more efficient NK cell-mediated response to Ab-coated targets (17, 35) . Thus, we compared degranulation and IFN-γ production in FcεRγ neg and FcεRγ + NK cells belonging to the memory NKG2C +
CD57
+ or to the NKG2C − CD57 + cell subsets against Rituximab-coated Raji cell line (see Figure 6A for gating strategy). In this set of experiments, NK cells isolated at 24 months after transplantation from HCMV-reactivating patients were analyzed. As shown in Figure 6B , FcεRγ neg and FcεRγ + NK cells were equally effective in terms of IFN-γ production, despite the fact that NKG2C +
+ FcεRγ neg cells expressed CD16 at lower levels ( Figure S4B in 
− cells strongly responded to uncoated Raji, thus making difficult to compare their response to mAbcoated Raji to that elicited by CD57 + cells (Figure 6B ). This high degranulation ability is likely to reflect a higher expression of NKp30 [which is primarily involved in the recognition of the B7-H6 + Raji cell line (36)], typical of less differentiated NK cells, as compared to CD57 + cells (data not shown) (37, 38) . Similar data were obtained in HCMV + HD (HD + ) (see Figure S6A in Supplementary Material).
Based on recent studies (32), in HD + adaptive FcεRγ neg NK cells displayed enhanced responses to CD16-mediated triggering when the CD2 co-receptor was simultaneously engaged. Notably, in the rituximab-coated-Raji assays such co-stimulation can always occur as Raji cells express CD58, the CD2 ligand, thus making the CD2-mediated increases not easily appreciable. Thus, we performed a more appropriate mAb-mediated crosslinking assay to better investigate the possible role of CD2 coengagement in the functional response mediated by FcεRγ neg and FcεRγ + NK cells derived from UCBT patients. As shown in Figure 6C , when CD16 and CD2 were simultaneously engaged by mAbmediated triggering, we could detect a modest increase in IFN-γ production and CD107a degranulation as compared to CD16 stimulation alone. This increase was significant only in NKG2 C + CD57 (Figure 6C) , although CD2 expression levels were lower than those found in NKG2C + NK cells (Figure 4 ; Figure S4B in Supplementary Material). Similar data were obtained in HD + (see Figure S6B in Supplementary Material).
In conclusion, we could not observe substantial differences in the effector function characterizing FcεRγ + and FcεRγ neg cells both in the memory-like NKG2C + CD57 + and in the NKG2C − CD57 + subset. This may indicate that full effector function and adaptive features (such as CD2-mediated enhancement of CD16 and NKG2C responses) could be achieved by HCMV-induced NK cells before and independently from FcεRγ downregulation after UCBT.
We next investigated whether, in UCBT recipients, adaptive NKG2C +
+ FcεRγ neg NK cells differentiating at late time points could be expanded upon exposure to a transfected cell line (721.221AEH, 221E for brevity) expressing the specific NKG2C ligand HLA-E (10, 39) . In CFSE proliferation assays, after 7-10 days coculture, we could detect a remarkable expansion of NKG2C 
DiscUssiOn
In the context of HCMV infection, human NK cells were shown to display unexpected adaptive traits, sharing features typical of T cells, including enhanced effector function, oligoclonal expansion, and long-term survival in response to a viral challenge (17, 23, 28, 33, 41, 43) . Although a precise phenotypic definition of adaptive NK cells cannot be provided, HCMV-induced expanded NK cells are mostly represented by terminally differentiated NKG2C (23, 24, 28, 33) . Importantly, according to recent studies in HCMV + HD, HCMVinduced NK cells display adaptive features including a decreased expression of signaling molecules (FcεRγ, SYK, EAT-2, DAB) and transcription factors (PLZF). Moreover, these cells can undergo epigenetic modifications that lead to changes in their phenotype (e.g., downregulated expression of CD161, CD7, Siglec-7, IL-12R, and IL-18R and upregulated expression of CD2 and LILRB1) and function (e.g., more efficient ADCC, lower response to IL-12 and IL-18) (16, 17) .
Notably, in view of the functional features and longevity of adaptive NK cells, they represent suitable candidates to be exploited in cellular immunotherapy against cancer. However, a better understanding of the mechanisms involved in the generation of this NK cell subset is necessary. With the purpose of clarifying these mechanisms and establishing at which stage the described adaptive features are acquired by NK cells upon HCMV encounter, we carried out a study in a cohort of patients undergoing UCBT. In this transplantation setting, HCMV infection/ reactivation is known to drive a strong NK cell skewing toward phenotypically and functionally polarized cell populations (23, 24) . Notably, NK cells are the first lymphocyte population which reconstitutes after transplantation and, thus, they may receive a strong imprinting by HCMV, especially in transplantation settings in which T cell immunity remains impaired for a prolonged period of time (44) . In this study, we show that certain adaptive characteristics are acquired early in UCBT recipients experiencing HCMV reactivation (within 6 months after UCBT), while others appear later and are confined to a small fraction of developing NK cells. In particular, our data indicate that HCMV induced a rapid reconfiguration of the surface phenotype, by promoting the expansion of NKG2C + CD57 + NK cells, mainly (31, 32, 43) . Accordingly, we found variable proportions of this NK cell subset in HCMV + HD (Figure 2A) (Figures 2 and 4B ; Figure S5 in Supplementary Material). This expression pattern differed from HCMV + HD, in which, in line with previous reports (16) , the majority of NKG2C +
CD57
+ NK cells displayed both PLZF and FcεRγ downregulation ( Figure 4B ). It cannot be ruled out that the PLFZ downregulation may precede the FcεRγ one in memory-like cells, contributing to the early reconfiguration of the NKG2C + cell subset. Indeed, PLZF can act as a transcriptional repressor, but can also induce gene expression. Thus, its absence may favor the acquisition of some adaptive features, for example by determining the low expression of IL-18R, IL-12R, and CD161 (16, 45) . Moreover, its absence may confer long-living properties, as suggested by data on MAIT cells, in which PLZF represents a pro-apoptotic factor (46) . On the other hand, in UCBT recipients, the two phenomena (PLZF and FcεRγ downregulation) occurred independently in different cells, since FcεRγ downregulation was detected in NKG2C − CD57 + NK cells that do not display a discrete PLZF downregulation at 24 months after transplantation ( Figure 4B ; Figure S5 in Supplementary Material).
It is possible that the partial differentiation of adaptive NK cells lacking FcεRγ downregulation could be related to the fact that repeated HCMV infection/reactivation episodes may be required to reach a stable epigenetic reprogramming, capable of silencing FcεRγ (16) . It is also possible that other viral infections (and/or vaccines) different from HCMV, frequently occurring in HD over the lifespan, may also play a role in shaping adaptive NK cell differentiation. Along this line, the generation of adaptive FcεRγ neg NK cells may require a network of signals and cellular interactions (e.g., cytokines or other soluble factors released at inflammatory sites, and/or interactions with infected targets, and/or humoral immunity responses) that could be temporarily altered in UCBT recipients in whom the acquisition of adaptive immunity occurs late. In this context, the presence of expanded adaptive NKG2C + NK cells that had not downregulated FcεRγ has been found also in TAP-deficient patients (47) . 
+ NK cells from UCBT patients were exposed to 221.AEH expressing the NKG2C ligand HLA-E, we could detect a prompt proliferative response of this subset independent of the expression of FcεRγ (Figure 7) . It is likely that the experimental system based on NKG2C stimulation through HLA-E + targets is not sufficient to provide stimuli capable of inducing either FcεRγ downregulation or a preferential expansion of FcεRγ neg cells. Indeed, according to other studies, FcεRγ neg NK cell proliferation is favored in the presence of IgG Abs engaging CD16 (16, 17) . Thus, we cannot exclude that the low percentage of FcεRγ neg NK cells may depend on compromised humoral responses in our UCBT recipients.
Another important issue concerns the possibility that adaptive NK cells may play a beneficial role in anti-leukemic responses after transplantation (33, 51) . Remarkably, FcεRγ neg adaptive NK cells have been described in HD to display a strong ADCC activity that can be further increased by CD2-mediated co-stimulation (32) . In our study, we could not detect relevant differences in the effector function (i.e., IFN-γ production and degranulation) of Figure S3C in Supplementary Material). However, the lower CD16 expression could be compensated by a stronger signal delivered by the adaptor signaling protein CD3ζ (containing three ITAMs) as compared to a weaker signal delivered by CD16 when it is coupled to FcεRγ (containing only 1 ITAM) (21, 22) .
Epigenetic and proteomic studies on larger cohorts of patients receiving UCBT are necessary for further unraveling the mechanisms behind adaptive NK cell generation, expansion, and longevity. However, our study highlights that, in UCBT recipients, HCMV reactivation may induce a rapid phenotypic reconfiguration including an early acquisition of certain adaptive features, while FcεRγ downregulation occurs only at later stages. Thus, while in these patients the complete acquisition of adaptive, HCMV-induced features by developing NK cells requires long time intervals, the rapid HCMV-driven reconfiguration is accompanied by the acquisition and persistence of the effector functions. This finding could be applied to design novel immunotherapeutic strategies (e.g., CAR-NK cells generation by manipulation of HCMV-induced long-living NK cell subsets) exploiting the functional potential of different subsets of adaptive NK cells, such as those emerging in UCBT recipients experiencing HCMV reactivation.
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